<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812940</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln 1717</org_study_id>
    <nct_id>NCT02812940</nct_id>
  </id_info>
  <brief_title>Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT</brief_title>
  <acronym>OCTET-Ever</acronym>
  <official_title>A Single-centre Study of Certican (Everolimus) as Prophylaxis for Graft-versus-Host Disease Following Post-Transplantation Cyclophosphamide After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II clinical study to assess the efficacy of short-term everolimus as prophylaxis for
      Graft-versus-Host disease (GvHD) in addition to post-transplantation cyclophosphamide after
      allogeneic hematopoietic stem cell transplantation in patients with haematological
      malignancies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title of the clinical study: A single-centre study of Certican (everolimus) as Prophylaxis
      for Graft-versus-Host Disease following Post-Transplantation Cyclophosphamide after
      Allogeneic Stem Cell Transplantation (OCTET-EVER)

      Indication: Patients with haematological malignancies after allogeneic haematopoietic stem
      cell transplantation with a matched related or unrelated donor following reduced intensity
      conditioning and post-transplantation cyclophosphamide

      Phase: Phase II clinical study

      Type of study, study design, methodology: Single centre single arm clinical trial, A'Hern's
      single stage phase II procedure

      Number of subjects: 20 (17 total evaluable)

      Primary study objective To assess the efficacy of short-term everolimus as GvHD prophylaxis
      in addition to post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell
      transplantation in patients with haematological malignancies and to describe the influence of
      the modified immunosuppression concept on the incidence and severity of acute GvHD, relapse
      rates, minimal residual disease, immune reconstitution and chimerism.

      Medical condition or disease to be investigated:

      • Patients with haematological malignancies after allogeneic haematopoietic stem cell
      transplantation with a matched related or unrelated donor following reduced intensity
      conditioning and post-transplantation cyclophosphamide

      Name of investigational medicinal product (IMP): Everolimus (Certican®) Investigational
      medicinal product - dosage and method of administration: 1,5mg per os twice a day (target
      blood level 5 to 10ng/ml) from day +5 to day +100 after allogeneic stem cell transplantation

      Duration of treatment: The treatment will be given from day +5 to day +100 after allogeneic
      stem cell transplantation. The observation time will last from day +5 to day +130. Incidence
      of chronic GvHD, overall survival and relapse incidence will be recorded on d+365 and d+720
      after transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute GvHD III-IV° until day +100 after allogenic stem cell transplantation</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>GvHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GvHD II-IV° until day +100 after allogenic stem cell transplantation</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe chronic GvHD</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>cGvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of overall chronic GvHD</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>cGvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>Relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>NRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>Number of CD3, CD4, CD8, CD20 and CD56 positive cells in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>absolute neutrophil count &gt; 500/ul and platelet count &gt; 50.000/ul</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>% donor cells in peripheral blood or bone marrow</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Graft-versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Everolimus as part of GvHD prophylaxis after allogeneic SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus from day +5 to day +100</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>GvHD prophylaxis</description>
    <arm_group_label>Everolimus as part of GvHD prophylaxis after allogeneic SCT</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with haematological malignancies after allogeneic haematopoietic stem cell
             transplantation with a matched related or unrelated donor following reduced intensity
             conditioning and post-transplantation cyclophosphamide

        Principal inclusion criteria:

        • Written informed consent

        Exclusion Criteria:

          -  Known intolerance to everolimus

          -  Presence or history of Microangiopathy

          -  Presence of uncontrolled infections

          -  Severe organ dysfunction defined as:

          -  Cardiac left ventricular ejection fraction (LVEF) of less than 35%

          -  Diffusing lung capacity (DLCO) of less than 40%

          -  Total lung capacity (TLC) of less than 40%

          -  Forced expiratory volume (FEV1) of less than 40%

          -  Total bilirubin &gt;3mg/dl

          -  Creatinine-clearance of less than 40 ml/min

          -  Pregnancy or breast feeding

          -  Participation in other experimental drug trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Scheid, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christof Scheid, Prof. Dr.</last_name>
    <phone>+49221478</phone>
    <phone_ext>6296</phone_ext>
    <email>c.scheid@uni-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Udo Holtick, PD Dr. Dr.</last_name>
    <phone>+49221478</phone>
    <phone_ext>4407</phone_ext>
    <email>udo.holtick@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Scheid, MD PhD</last_name>
      <phone>49221478</phone>
      <phone_ext>6296</phone_ext>
      <email>c.scheid@uni-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Udo Holtick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Christoph Scheid</investigator_full_name>
    <investigator_title>Prof. Dr. Christoph Scheid</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

